Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Short Interest Update

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) was the target of a large growth in short interest in February. As of February 28th, there was short interest totalling 17,500 shares, a growth of 3,400.0% from the February 13th total of 500 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average daily volume of 318,700 shares, the days-to-cover ratio is presently 0.1 days.

Provectus Biopharmaceuticals Stock Down 3.5 %

Shares of PVCT opened at $0.10 on Friday. The firm’s 50 day simple moving average is $0.11 and its 200 day simple moving average is $0.11. Provectus Biopharmaceuticals has a 1-year low of $0.04 and a 1-year high of $0.22.

About Provectus Biopharmaceuticals

Provectus Biopharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis.